VWF and neoplasm: We used an engineered form for both cytokines to improve their biodistribution, leveraging our reported tumor stroma–binding technology, which uses a collagen-binding domain (CBD) derived from the A3 domain of von Willebrand factor as a tumor retention domain (22–25).